Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabies PrEP and Simulated PEP Regimens
NCT03700242Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rabies virus inactivated antigen, B and rabies virus inactivated antigen, A in rabies (5 arms), sponsored by Sanofi. Primary endpoint: Seroconversion of participant. Started Sep 2018; status: completed.
02
Drugs
rabies virus inactivated antigen, Brabies virus inactivated antigen, A
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03700242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700242.